

Claims

1. Use of appropriate doses of an LHRH-antagonist, peptidic or non-peptidic, that will lower sex hormone levels to a certain extent but not below the castration level.
2. Use of appropriate doses of an LHRH-antagonist to lower sex hormone levels resulting in modification of the T-cell population.
3. Use of appropriate doses of an LHRH-antagonist to lower sex hormone levels resulting in a modification of the T-cell population in an individual suffering from a disease that will respond favourably to such a modification.
4. Use of appropriate doses of an LHRH-antagonist to lower sex hormone levels resulting in a modification of the T-cell population in an individual suffering from a HIV infection, cancer, an auto-immune disease, benign prostatic hyperplasia, endometriosis, asthma, arthritis, dermatitis, multiple sclerosis, Jacob Creutzfeldt-disease, Alzheimer's disease and for anti-aging-treatment.
5. Use of appropriate doses of an LHRH-antagonist to lower sex hormone levels resulting in a modification of the T-cell population resulting in an enhanced immune response to an antigen.
6. Use of appropriate doses of an LHRH-antagonist to lower sex hormone levels resulting in a modification of the T-cell population resulting in a decrease of host versus graft reaction.
7. Examples for substances that can be used as LHRH-antagonists according to claims 1 – 6 are cetrorelix, teverelix, antide, or abarelix.
8. Use of a LHRH-antagonist for producing a medicament for the treatment of diseases according to claims 1 to 7.

9. Use according to claim 8, characterized in that the LHRH-antagonist is administered in the following total dose from 5 mg to 120 mg divided in a period of 1 to 8 weeks and according to needs with repeat of the therapy every 3 to 4 months.
10. Use according to claims 8 and 9, characterized in that cetorelix pamoate is administered in the following total dose from 30 mg to 120 mg divided in a period of 1 to 4 weeks and according to needs with repeat of the therapy every 3 to 4 months.
11. Use according to claims 8 and 9, characterized in that cetorelix acetate is administered in the following total dose from 5 mg to 80 mg divided in a period of 1 to 8 weeks and according to needs with repeat of the therapy every 3 to 4 months.